

Xavier Kurz

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7103728/xavier-kurz-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43
papers

741
citations

17
h-index

26
g-index

46
ext. papers

1,005
ext. citations

4.3
avg, IF

4.68
L-index

#	Paper	IF	Citations
43	Marketing Authorization Applications Made to the European Medicines Agency in 2018-2019: What was the Contribution of Real-World Evidence?. <i>Clinical Pharmacology and Therapeutics</i> , 2021 ,	6.1	6
42	Increasing the impact of Post Authorisation Safety Studies: transparency is key. <i>European Journal of Internal Medicine</i> , 2021 , 83, 6-7	3.9	0
41	Does additional monitoring status increase the reporting of adverse drug reactions? An interrupted time series analysis of EudraVigilance data. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 350-359	2.6	3
40	What are the patients and health care professionals understanding and behaviors towards adverse drug reaction reporting and additional monitoring?. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 334-341	2.6	4
39	International Collaboration in Real-World Evidence Generation for Direct Acting Oral Anti-Coagulants. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 299-301	6.1	1
38	Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 825-831	2.6	18
37	Regulatory and health technology assessment advice on postlicensing and postlaunch evidence generation is a foundation for lifecycle data collection for medicines. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 1034-1051	3.8	18
36	Ability of Primary Care Health Databases to Assess Medicinal Products Discussed by the European Union Pharmacovigilance Risk Assessment Committee. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 957-965	6.1	1
35	Can We Rely on Results From IQVIA Medical Research Data UK Converted to the Observational Medical Outcome Partnership Common Data Model?: A Validation Study Based on Prescribing Codeine in Children. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 915-925	6.1	3
34	Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines. <i>Vaccine</i> , 2020 , 38 Suppl 2, B1-B7	4.1	11
33	Association between hydrochlorothiazide exposure and different incident skin, lip and oral cavity cancers: A series of population-based nested case-control studies. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 1336-1345	3.8	17
32	Assessing strength of evidence for regulatory decision making in licensing: What proof do we need for observational studies of effectiveness?. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 1336-1340	2.6	4
31	Prescribing patterns of tramadol in adults in IMS primary care databases in France and Germany between 1 January 2006 and 30 June 2016. <i>European Journal of Clinical Pharmacology</i> , 2019 , 75, 707-716	2.8	7
30	A European multicentre drug utilisation study of the impact of regulatory measures on prescribing of codeine for pain in children. <i>Pharmacoepidemiology and Drug Safety</i> , 2019 , 28, 1086-1096	2.6	11
29	Barriers and Opportunities for Use of Patient Registries in Medicines Regulation. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 39-42	6.1	8
28	Guidance for the governance of public-private collaborations in vaccine post-marketing settings in Europe. <i>Vaccine</i> , 2019 , 37, 3278-3289	4.1	8
27	Association Between Peripheral Neuropathy and Exposure to Oral Fluoroquinolone or Amoxicillin-Clavulanate Therapy. <i>JAMA Neurology</i> , 2019 , 76, 827-833	17.2	28

26	Effect of withdrawal of fusafungine from the market on prescribing of antibiotics and other alternative treatments in Germany: a pharmacovigilance impact study. <i>European Journal of Clinical Pharmacology</i> , 2019 , 75, 979-984	2.8	7
25	The ENCePP Code of Conduct: A best practise for scientific independence and transparency in noninterventional postauthorisation studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2019 , 28, 422-433	2.6	6
24	Real-World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 36-39	6.1	89
23	Patient Registries: An Underused Resource for Medicines Evaluation : Operational proposals for increasing the use of patient registries in regulatory assessments. <i>Drug Safety</i> , 2019 , 42, 1343-1351	5.1	35
22	Addendum to: Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case-Control Study. <i>Clinical Drug Investigation</i> , 2019 , 39, 591-594	3.2	6
21	AuthorsRRReply to Ravi JandhyalaR Comment on "Patient Registries: An Underused Resource for Medicines Evaluation: Operational Proposals for Increasing the Use of Patient Registries in Regulatory Assessments". <i>Drug Safety</i> , 2019 , 42, 1517-1518	5.1	
20	Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case-Control Study. <i>Clinical Drug Investigation</i> , 2019 , 39, 205-213	3.2	26
19	Strengthening standards, transparency, and collaboration to support medicine evaluation: Ten years of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 245-252	2.6	23
18	EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection. <i>Drug Safety</i> , 2018 , 41, 665-675	5.1	34
17	Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations. <i>BMC Medicine</i> , 2018 , 16, 6	11.4	54
16	Indications for Systemic Fluoroquinolone Therapy in Europe and Prevalence of Primary-Care Prescribing in France, Germany and the UK: Descriptive Population-Based Study. <i>Clinical Drug Investigation</i> , 2018 , 38, 927-933	3.2	10
15	Measuring the impact of medicines regulatory interventions - Systematic review and methodological considerations. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 419-433	3.8	45
14	Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation. <i>BMJ Open</i> , 2018 , 8, e203090	3	23
13	Imposed registries within the European postmarketing surveillance system: Extended analysis and lessons learned for regulators. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 823-826	2.6	6
12	Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 1442-1450	2.6	25
11	The ADVANCE Code of Conduct for collaborative vaccine studies. <i>Vaccine</i> , 2017 , 35, 1844-1855	4.1	15
10	Advancing regulatory science, advancing regulatory practice. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 722-726	2.6	2
9	Antiepileptic drugs and risk of suicide attempts: a case-control study exploring the impact of underlying medical conditions. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 239-247	2.6	8

8	Application of real-time global media monitoring and derived questions for enhancing communication by regulatory bodies: the case of human papillomavirus vaccines. <i>BMC Medicine</i> , 2017 , 15, 91	11.4	14
7	Patterns of spontaneous reports on narcolepsy following administration of pandemic influenza vaccine; a case series of individual case safety reports in Eudravigilance. <i>Vaccine</i> , 2016 , 34, 4892-4897	4.1	9
6	Calcium channel blockers and cancer: a risk analysis using the UK Clinical Practice Research Datalink (CPRD). <i>BMJ Open</i> , 2016 , 6, e009147	3	34
5	Multi-centre, multi-database studies with common protocols: lessons learnt from the IMI PROTECT project. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25 Suppl 1, 156-65	2.6	33
4	Autoimmune disorders after immunisation with Influenza A/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review. <i>Vaccine</i> , 2012 , 30, 7123-9	4.1	40
3	Increasing scientific standards, independence and transparency in post-authorisation studies: the role of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. <i>Pharmacoepidemiology and Drug Safety</i> , 2012 , 21, 690-696	2.6	24
2	Safety monitoring of Influenza A/H1N1 pandemic vaccines in EudraVigilance. <i>Vaccine</i> , 2011 , 29, 4378-87	4.1	19
1	The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance: application to diabetes and vascular disease. <i>British Journal of Diabetes and Vascular Disease</i> , 2011 , 11, 304-307		4